资源描述：
《中药护肝i号联合恩替卡韦治疗慢性乙型肝炎200例疗效分析》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、中药护肝I号联合恩替卡韦治疗慢性乙型肝炎200例疗效分析蒋跃倪辉程书权(广西桂林市第三人民医院肝病科541002)【摘要】目的：用屮药护肝I号联合恩替卡韦，治疗慢性病毒乙肝的疗效探讨；方法：选择初治慢性乙肝患者400例，随机分成治疗组和对照组各200例，治疗组采用屮药护肝I号，恩替卡韦分散片；对照组单纯采用恩替卡韦分散片;观察两组病人治疗后的生化、病毒、以及T细胞指数的变化；结果：治疗组显效率明显高于对照组.两组治疗后肝功能、HBV-DNA水平均明显下降,HBeAg/HBeAb转换率高，CD4+水平明显升高(P<0.05),
2、CD8+明显K降(P<0.05);两组患者服药24个月停药,3个月后检查，肝功能、HBV-DNA,治疗组反弹率为5.50%，对照组反弹率为44.00%，两组存在显著差别(P<0.01);结论：屮药护肝I号治疗慢性乙型肝炎可以提高恩替卡韦抗乙肝病毒的疗效，降低反弹率。【关键词】乙型肝炎屮医治疗免疫调节T细胞免疫功能【屮图分类号】R969.4【文献标识码】A【文章编号】1672-5085(2014)09-0009-02ResearchandClinicalObservationforImmunityMechanismofT
3、raditionalChineseMedicineImmunityReformingmethodintreatmentofchronichepatitisB.JiangYue,NiHui.DivisionofLiverDiseasesofTheThirdPeople’sHospitalofGuilin,Guangxi,541002【ABSTRACT】Purpose.ByusingtraditionalChinesemedicinedialecticalmethod,reformingImmunitytoenhancet
4、herapeuticefficacythatnucleosideanalogsinhibitHBV,aswellasexploreit’simmunitymechanism.Method.：Selecting400casespatientswithchronichepatitisb(CHB)anddividethemintotwogroups,treatmentgroupandcontrolgroup.Treatmentgroup,usingtraditionalChinesemedicinemodifieddecoc
5、tionforinvigoratingthespleenandkidney,androutineEntecavirDispersibleTablets.Controlgroup,onlyusingEntecavirDispersibleTablets.Observingtheirclinicalefficacyandcellcularimmunitychangesaftertreating.Result.SignificantlyeffectiverateofTraditionalChineseMedicineImmunityRe
6、formingMethodisobviouslyhigherthancontrolgroup(P<O.Ol).Aftertreatmentoftwogroups,theirstandardsofliverfunction,HBV-DNAarebothdecreasedsignificantly(P<0.01,P<0.05).Thetreatmentgroup’sturnoverrateishighaftertreating,standardofCD4+isobviouslyincreased(P<
7、;0.05),andCD8+isobviouslydecreased(P<0.05).Thecontrolgroup’sstandardsofCD4+andCD8+isbothwithoutsignificantchanges(P>0.05).Drugwithdrawalwhentwogroup’spatientstakingmedicinefor24months,andtesttheirliverfunctionandHBV-DNA,thebouncerateoftreatmentgroupi
8、s5.50%,and44.00%ofcontrolgroup.Therearesignificantdifferencesbetweenthem(P<0.01).Conclusion.TraditionalChineseMedicineRef
